SCHEMBL116102

SCHEMBL116102

Nc1ccc2ccncc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 1/20 0.71
MAPT P10636 1/20 0.53
CYP3A4 P08684 4/20 0.50
ALDH1A1 P00352 2/20 0.50
HSD17B10 Q99714 2/20 0.50
EGFR P00533 2/20 0.48
CLK1 P49759 2/20 0.47
CSNK1D P48730 1/20 0.47
CSNK1E P49674 1/20 0.47
DYRK1A Q13627 1/20 0.47
IMPDH2 P12268 3/20 0.47
LMNA P02545 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
MELK Q14680 1/20 0.44
IKBKB O14920 1/20 0.44
MAPK10 P53779 1/20 0.44
PLAU P00749 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30279711 1.00 PRKCZ (0.71) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL112842 0.91 PRKCZ (0.60) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL30579694 0.91 PRKCZ (0.60) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL29417996 0.91 PRKCZ (0.60) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL14563529 0.89 PRKCZ (0.58) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL27809127 0.89 PRKCZ (0.58) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
Quinoline SCHEMBL28085853 0.82 ALDH1A1 (0.60) PRKCZMAPTCYP3A4ALDH1A1HSD17B10
SCHEMBL29450635 0.79 PRKCZ (0.72) PRKCZCYP3A4LMNACYP1A2CYP2D6
SCHEMBL2887108 0.78 PRKCZ (0.64) PRKCZCYP3A4EGFRCYP1A2CYP2D6
SCHEMBL23443647 0.77 PRKCZ (0.47) PRKCZMAPTCYP3A4ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800909-A Synthetic method of nitrogen-containing aromatic heterocyclic methylamine 北京六合宁远医药科技股份有限公司 2024-04-02 CN claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
EP-2970215-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-20 EP claimed
US-8871757-B2 6-and 7-amino isoquinoline compounds and methods for making and using the same AERIE PHARMACEUTICALS, INC. (US) 2014-10-28 US claimed
WO-2014140310-A1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 WO claimed
CN-102875465-A Method for preparing 7-bromoisoquinoline UNIV SHANGHAI 2013-01-16 CN claimed
EP-2546237-A1 7-AMINO ISOQUINOLINS COMPOUNDS AND METHODS FOR MAKING THE SAME AERIE PHARMACEUTICALS, INC. (US) 2013-01-16 EP claimed
EP-2252589-A2 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME Aerie Pharmaceuticals, Inc. (US) 2010-11-24 EP claimed
US-20100144713-A1 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME AERIE PHARMACEUTICALS, INC. (US) 2010-06-10 US claimed
US-20090186917-A1 6-And 7-amino isoquinoline compounds and methods for making and using the same AERIE PHARMACEUTICALS, INC. (US) 2009-07-23 US claimed
WO-2009091898-A2 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME AERIE PHARMACEUTICALS, INC. (US) 2009-07-23 WO claimed
EP-4720067-A1 BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY Recursion Pharmaceuticals, Inc. (US) 2026-04-08 EP disclosed
CN-121108048-A Synthesis method of 7-aminoisoquinoline 上海毕得医药科技股份有限公司 2025-12-12 CN disclosed
CN-121108048-A Synthesis method of 7-aminoisoquinoline 上海毕得医药科技股份有限公司 2025-12-12 CN disclosed
EP-4615838-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS Merck Patent GmbH (DE) 2025-09-17 EP disclosed
US-4258049-A Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines SMITHKLINE CORPORATION (US) 1981-03-24 US disclosed
EP-0023761-A1 Tetrahydroisoquinoline derivatives, process for preparing them and compositions containing them SMITHKLINE BECKMAN CORPORATION (US) 1981-02-11 EP disclosed
US-4062961-A SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES SMITHKLINE CORPORATION (US) 1977-12-13 US disclosed
US-4022900-A Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents MARION LABORATORIES, INC. (US) 1977-05-10 US disclosed
US-3988339-A 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE SMITHKLINE CORPORATION (US) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144713-A1 6-AND 7-AMINO ISOQUINOLINE COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME COQ8A, MAP3K7, PRKG2 PRKCZ 138/4885MAPT 1675/4885CYP3A4 1313/4885
US-20090186917-A1 6-And 7-amino isoquinoline compounds and methods for making and using the same COQ8A, MAP3K7, PRKG2 PRKCZ 138/4885MAPT 1675/4885CYP3A4 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.